Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
about
Anti-hypertensive drugs in children and adolescentsSpironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signalingA physiological concept unmasking vascular salt sensitivity in manA review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice.Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Renal denervation therapy for resistant hypertension: a clinical update.Drug-induced hyperkalemia.Reviving the use of aldosterone inhibitors in treating hypertension in obesity.Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease.Management of Hypertension in Primary Care Safety-Net Clinics in the United States: A Comparison of Community Health Centers and Private Physicians' Offices.Na+ homeostasis by epithelial Na+ channel (ENaC) and Nax channel (Nax): cooperation of ENaC and Nax.Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
P2860
Q33772773-9D03227E-713F-472C-A3AE-069E6F74C995Q36121902-53946C2E-2191-44EC-9274-FA95674A3CFAQ36177251-CB7259FE-986E-421E-B95A-697DF340DBDFQ37471525-E1458729-7B8A-4030-B79E-D18482938AD1Q37595772-F8EE8662-DC68-4931-BA37-1C0D21E852FDQ38077678-B572075F-3FCA-4AB4-BCAD-A646D2C18A70Q38193683-8E0F3CFB-5996-4A29-B20F-D1BD2644EBA8Q38232308-63EFE209-612E-400E-AF26-93B3B2A0E07CQ38544250-984B0637-C9F1-4A26-9CF1-39349A79C930Q38987673-12BE0F9B-E6E5-4727-A550-F495304CDAEEQ39695053-C894B158-1A5F-485A-8CF2-A1805228413FQ42370381-8E762764-F3CD-4439-815E-C7D7B410D87DQ47120314-8D06F0BA-2C58-43CE-834A-FF65D7BB62FFQ51748655-43EAB530-1759-4F0E-B48F-C3AA846F8D3FQ54603457-412198B1-1B75-4505-9F2D-FD31DB271AB3Q57911462-93A6D034-DF62-4BD6-8D23-97E15A2DF38A
P2860
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Aldosterone blockers (mineralo ...... d potassium-sparing diuretics.
@en
Aldosterone blockers
@nl
type
label
Aldosterone blockers (mineralo ...... d potassium-sparing diuretics.
@en
Aldosterone blockers
@nl
prefLabel
Aldosterone blockers (mineralo ...... d potassium-sparing diuretics.
@en
Aldosterone blockers
@nl
P2860
P1476
Aldosterone blockers (mineralo ...... d potassium-sparing diuretics.
@en
P2093
David A Calhoun
Murray Epstein
P2860
P304
P356
10.1111/J.1751-7176.2011.00511.X
P577
2011-08-09T00:00:00Z